Morgan Stanley upgraded Ascendis Pharma (ASND) to Overweight from Equal Weight with a price target of $250, up from $180. The firm says the first quarter of the U.S. Yorvipath performance was ahead of its expectations, suggesting the potential for 2025 performance to drive consensus higher over the coming quarters. While the launch remains early, initial metrics provide an “encouraging read to provider appetite, prescription growth, and payor receptivity,” the analyst tells investors in a research note. Morgan sees Yorvipath as the key driver of Ascendis in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Earnings Call: Growth Amid Challenges
- Ascendis Pharma price target raised to $215 from $180 at Oppenheimer
- Ascendis Pharma price target raised to $210 from $205 at RBC Capital
- Ascendis Pharma price target raised to $212 from $181 at Wedbush
- Ascendis Pharma price target raised to $245 from $200 at JPMorgan